A Prospective Randomized Open-labeled Trial Comparing RADIOEMBOLIZATION With Yttrium 90 Microspheres and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Sorafenib (Primary) ; Yttrium-90 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SARAH
- 26 Oct 2017 Results (n=467, randomized between Dec 5, 2011, and March 12, 2015) published in the Lancet Oncology
- 04 Mar 2015 Results are expected in late 2016, according to a media release.
- 04 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to a media release.